James M. Markert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James M. Markert has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth A. Beierle
Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
3 shared publications - G. Yancey Gillespie
Department of Neurosurgery
3 shared publications - Gregory K. Friedman
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications Alfred D Lakeman
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA
2 shared publications- Cheryl Ann Palmer
Department of Pathology, University of Utah, Salt Lake City, UT, USA
2 shared publications G Y Gillespie
1] Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA [2] Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA
2 shared publications
Latest Publications
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S105-S106
Oncolytic Herpes Simplex Virus Decreased Rhabdomyosarcoma Cell Survival In Vitro and In Vivo
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S105-S106
Oncolytic Herpes Simplex Virus Decreased Rhabdomyosarcoma Cell Survival In Vitro and In Vivo
- 1 September 2014
- Published by Defense Technical Information Center (DTIC)
Engineered Herpes Simplex Viruses for the Treatment of Malignant Peripheral Nerve Sheath Tumors
A significant proportion of patients with neurofibromatosis type I (NF-1) will develop benign neurofibromas in their peripheral nerves that will progress to malignant tumors that are called malignant peripheral nerve sheath tumors or MPNST. These tumors grow progressively and if they cannot be completely removed surgically, they are eventually fatal. Radiation provides some benefit but is mostly ineffective and there are no proven chemotherapy type drugs or medicines that will prevent the progressive growth of these tumors. We have been working with genetically engineered human herpes simplex virus (HSV) as a means of treating nervous system tumors. We have genetically modified these viruses to make them safe and unable to grow in normal cells, but they will grow in tumor cells and will eventually cause the tumor cells to die, a process called oncolysis (tumor lysis). In addition, we have inserted several different kinds of genes in these viruses that allow them to overcome different mechanisms that tumor cells have to prevent virus growth. Our objective is to determine whether or not MPNST cells can be infected and killed by our oHSVs. We will test our panel of viruses against a panel of mouse and human MPNST cells that are maintained in tissue culture. We will examine the molecular changes in this large panel of tumor cells (tumor genotype) to determine how each virus is able to overcome each tumor s anti-virus defenses. We believe that all possible anti-virus defense mechanisms would be represented in our panel of both mouse and human MPNSTs and that we will be able to match the most effective oHSV engineered to overcome that mechanism used to block the virus.
- 1 September 2014
- Published by Defense Technical Information Center (DTIC)
Engineered Herpes Simplex Viruses for the Treatment of Malignant Peripheral Nerve Sheath Tumors
A significant proportion of patients with neurofibromatosis type I (NF-1) will develop benign neurofibromas in their peripheral nerves that will progress to malignant tumors that are called malignant peripheral nerve sheath tumors or MPNST. These tumors grow progressively and if they cannot be completely removed surgically, they are eventually fatal. Radiation provides some benefit but is mostly ineffective and there are no proven chemotherapy type drugs or medicines that will prevent the progressive growth of these tumors. We have been working with genetically engineered human herpes simplex virus (HSV) as a means of treating nervous system tumors. We have genetically modified these viruses to make them safe and unable to grow in normal cells, but they will grow in tumor cells and will eventually cause the tumor cells to die, a process called oncolysis (tumor lysis). In addition, we have inserted several different kinds of genes in these viruses that allow them to overcome different mechanisms that tumor cells have to prevent virus growth. Our objective is to determine whether or not MPNST cells can be infected and killed by our oHSVs. We will test our panel of viruses against a panel of mouse and human MPNST cells that are maintained in tissue culture. We will examine the molecular changes in this large panel of tumor cells (tumor genotype) to determine how each virus is able to overcome each tumor s anti-virus defenses. We believe that all possible anti-virus defense mechanisms would be represented in our panel of both mouse and human MPNSTs and that we will be able to match the most effective oHSV engineered to overcome that mechanism used to block the virus.
- 14 August 2014
- Published by Springer Nature in Gene Therapy
- Vol. 21 (11) , 984-990
Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines
Limited expression and distribution of nectin-1, the major herpes simplex virus (HSV) type-1 entry-receptor, within tumors has been proposed as an impediment to oncolytic HSV (oHSV) therapy. To determine whether resistance to oHSVs in malignant peripheral nerve sheath tumors (MPNSTs) was explained by this hypothesis, nectin-1 expression and oHSV viral yields were assessed in a panel of MPNST cell lines using γ134.5-attenuated (Δγ134.5) oHSVs and a γ134.5 wild-type (wt) virus for comparison. Although there was a correlation between nectin-1 levels and viral yields with the wt virus (R=0.75, P =0.03), there was no correlation for Δγ134.5 viruses (G207, R7020 or C101) and a modest trend for the second-generation oHSV C134 (R=0.62, P=0.10). Nectin-1 overexpression in resistant MPNST cell lines did not improve Δγ134.5 oHSV output. While multistep replication assays showed that nectin-1 overexpression improved Δγ134.5 oHSV cell-to-cell spread, it did not confer a sensitive phenotype to resistant cells. Finally, oHSV yields were not improved with increased nectin-1 in vivo. We conclude that nectin-1 expression is not the primary obstacle of productive infection for Δγ134.5 oHSVs in MPNST cell lines. In contrast, viruses that are competent in their ability to counter the antiviral response may derive benefit with higher nectin-1 expression.
- 14 August 2014
- Published by Springer Nature in Gene Therapy
- Vol. 21 (11) , 984-990
Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines
Limited expression and distribution of nectin-1, the major herpes simplex virus (HSV) type-1 entry-receptor, within tumors has been proposed as an impediment to oncolytic HSV (oHSV) therapy. To determine whether resistance to oHSVs in malignant peripheral nerve sheath tumors (MPNSTs) was explained by this hypothesis, nectin-1 expression and oHSV viral yields were assessed in a panel of MPNST cell lines using γ134.5-attenuated (Δγ134.5) oHSVs and a γ134.5 wild-type (wt) virus for comparison. Although there was a correlation between nectin-1 levels and viral yields with the wt virus (R=0.75, P =0.03), there was no correlation for Δγ134.5 viruses (G207, R7020 or C101) and a modest trend for the second-generation oHSV C134 (R=0.62, P=0.10). Nectin-1 overexpression in resistant MPNST cell lines did not improve Δγ134.5 oHSV output. While multistep replication assays showed that nectin-1 overexpression improved Δγ134.5 oHSV cell-to-cell spread, it did not confer a sensitive phenotype to resistant cells. Finally, oHSV yields were not improved with increased nectin-1 in vivo. We conclude that nectin-1 expression is not the primary obstacle of productive infection for Δγ134.5 oHSVs in MPNST cell lines. In contrast, viruses that are competent in their ability to counter the antiviral response may derive benefit with higher nectin-1 expression.
- Open Access
- 1 May 2014
- Published by Elsevier in Molecular Therapy
- Vol. 22 (5) , 1048-1055
A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
- 1 May 2014
- Published by Elsevier in Molecular Therapy
- Vol. 22 (5) , 1048-1055
Open AccessA Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
- Open Access
- 1 May 2014
- Published by Elsevier in Molecular Therapy
- Vol. 22 (5) , 1056-1062
Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
- 1 May 2014
- Published by Elsevier in Molecular Therapy
- Vol. 22 (5) , 1056-1062
Open AccessPhase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
- 1 March 2014
- Published by SAGE Publications in Human Gene Therapy Clinical Development
- Vol. 25 (1) , 16-27
Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates
Herpes simplex virus type 1 (HSV-1) mutants lacking the γ134.5 neurovirulence loci are promising agents for treating malignant glioma. Arming oncolytic HSV-1 to express immunostimulatory genes may potentiate therapeutic efficacy. We have previously demonstrated improved preclinical efficacy, biodistribution, and safety of M002, a γ134.5-deleted HSV-1 engineered to express murine IL-12. Herein, we describe the safety and biodistribution of M032, a γ134.5-deleted HSV-1 virus that expresses human IL-12 after intracerebral administration to nonhuman primates, Aotus nancymae. Cohorts were administered vehicle, 106, or 108 pfu of M032 on day 1 and subjected to detailed clinical observations performed serially over a 92-day trial. Animals were sacrificed on days 3, 31, and 91 for detailed histopathologic assessments of all organs and to isolate and quantify virus in all organs. With the possible exception of one animal euthanized on day 16, neither adverse clinical signs nor sex- or dose-related differences were attributed to M032. Elevated white blood cell and neutrophil counts were observed in virus-injected groups on day 3, but no other significant changes were noted in clinical chemistry or coagulation parameters. Minimal to mild inflammation and fibrosis detected, primarily in meningeal tissues, in M032-injected animals on days 3 and 31 had mostly resolved by day 91. The highest viral DNA levels were detected at the injection site and motor cortex on day 3 but decreased in central nervous system tissues over time. These data demonstrate the requisite safety of intracerebral M032 administration for consideration as a therapeutic for treating malignant brain tumors.
- 1 March 2014
- Published by SAGE Publications in Human Gene Therapy Clinical Development
- Vol. 25 (1) , 16-27
Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates
Herpes simplex virus type 1 (HSV-1) mutants lacking the γ134.5 neurovirulence loci are promising agents for treating malignant glioma. Arming oncolytic HSV-1 to express immunostimulatory genes may potentiate therapeutic efficacy. We have previously demonstrated improved preclinical efficacy, biodistribution, and safety of M002, a γ134.5-deleted HSV-1 engineered to express murine IL-12. Herein, we describe the safety and biodistribution of M032, a γ134.5-deleted HSV-1 virus that expresses human IL-12 after intracerebral administration to nonhuman primates, Aotus nancymae. Cohorts were administered vehicle, 106, or 108 pfu of M032 on day 1 and subjected to detailed clinical observations performed serially over a 92-day trial. Animals were sacrificed on days 3, 31, and 91 for detailed histopathologic assessments of all organs and to isolate and quantify virus in all organs. With the possible exception of one animal euthanized on day 16, neither adverse clinical signs nor sex- or dose-related differences were attributed to M032. Elevated white blood cell and neutrophil counts were observed in virus-injected groups on day 3, but no other significant changes were noted in clinical chemistry or coagulation parameters. Minimal to mild inflammation and fibrosis detected, primarily in meningeal tissues, in M032-injected animals on days 3 and 31 had mostly resolved by day 91. The highest viral DNA levels were detected at the injection site and motor cortex on day 3 but decreased in central nervous system tissues over time. These data demonstrate the requisite safety of intracerebral M032 administration for consideration as a therapeutic for treating malignant brain tumors.
- 30 September 2012
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 215 (3) , S69-S70
Oncolytic herpes simplex virus and radiation combination therapy results in a systemic immune response to inhibit neuroblastoma tumor growth
- 30 September 2012
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 215 (3) , S69-S70
Oncolytic herpes simplex virus and radiation combination therapy results in a systemic immune response to inhibit neuroblastoma tumor growth
- 1 September 2011
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 213 (3) , S76
Combination treatment with genetically altered oncolytic herpes simplex virus and low-dose irradiation inhibits neuroblastoma tumor growth
- 1 September 2011
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 213 (3) , S76
Combination treatment with genetically altered oncolytic herpes simplex virus and low-dose irradiation inhibits neuroblastoma tumor growth
- 1 January 2011
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 68 (1) , 85-88
Risk Factors for Conversion to Permanent Ventricular Shunt in Patients Receiving Therapeutic Ventriculostomy for Traumatic Brain Injury
Intracranial pressure is routinely monitored in patients with severe traumatic brain injury (TBI). Patients with TBI sometimes develop hydrocephalus, requiring permanent cerebrospinal fluid (CSF) diversion. To quantify the need for permanent CSF diversion in patients with TBI. Patients who received a ventriculostomy after TBI between June 2007 and July 2008 were identified, and their medical records were abstracted to a database. Sixteen of 71 patients (22.5%) receiving a ventriculostomy required a ventriculoperitoneal or ventriculoatrial shunt before discharge from the hospital. The average number of days between ventriculostomy and shunt was 18.3. Characteristics that predispose these patients to require permanent CSF diversion include the need for craniotomy within 48 hours of admission (odds ratio, 5.20; 95% confidence interval, 1.48-18.35) and history of culture-positive CSF (odds ratio, 5.52; 95% confidence interval, 1.19-25.52). Length of stay was increased in patients receiving permanent CSF diversion (average length of stay, 61 vs 31 days; P = .04). Patient discharge disposition was similar between shunted and nonshunted patients. In this retrospective study, 22% of TBI patients who required a ventriculostomy eventually needed permanent CSF diversion. Patients with TBI should be assessed for the need for permanent CSF diversion before discharge from the hospital. Care must be taken to prevent ventriculitis. Future studies are needed to evaluate more thoroughly the risk factors for the need for permanent CSF diversion in this patient population.
- 1 January 2011
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 68 (1) , 85-88
Risk Factors for Conversion to Permanent Ventricular Shunt in Patients Receiving Therapeutic Ventriculostomy for Traumatic Brain Injury
Intracranial pressure is routinely monitored in patients with severe traumatic brain injury (TBI). Patients with TBI sometimes develop hydrocephalus, requiring permanent cerebrospinal fluid (CSF) diversion. To quantify the need for permanent CSF diversion in patients with TBI. Patients who received a ventriculostomy after TBI between June 2007 and July 2008 were identified, and their medical records were abstracted to a database. Sixteen of 71 patients (22.5%) receiving a ventriculostomy required a ventriculoperitoneal or ventriculoatrial shunt before discharge from the hospital. The average number of days between ventriculostomy and shunt was 18.3. Characteristics that predispose these patients to require permanent CSF diversion include the need for craniotomy within 48 hours of admission (odds ratio, 5.20; 95% confidence interval, 1.48-18.35) and history of culture-positive CSF (odds ratio, 5.52; 95% confidence interval, 1.19-25.52). Length of stay was increased in patients receiving permanent CSF diversion (average length of stay, 61 vs 31 days; P = .04). Patient discharge disposition was similar between shunted and nonshunted patients. In this retrospective study, 22% of TBI patients who required a ventriculostomy eventually needed permanent CSF diversion. Patients with TBI should be assessed for the need for permanent CSF diversion before discharge from the hospital. Care must be taken to prevent ventriculitis. Future studies are needed to evaluate more thoroughly the risk factors for the need for permanent CSF diversion in this patient population.
- Top Cited PapersOpen Access
- 1 January 2009
- Published by Elsevier in Molecular Therapy
- Vol. 17 (1) , 199-207
Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM
- 1 January 2009
- Published by Elsevier in Molecular Therapy
- Vol. 17 (1) , 199-207
Top Cited PapersOpen AccessPhase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM